Neuro-Oncology - Science topic

To any peer-reviewed journal of neurosurgery or neuro-oncology.

Dear Alothman,

First I congratulate you for your motivation of the research. The following important point must be in your mind. There are often times when added research would be required to make it easier for a study to go forward. Your research plans could include an analysis of the methods of study that could work in the future and what points about a topic could be reviewed in such studies. The recommendations that are incorporated into your paper can certainly be important to your work. Be certain when writing your paper that you have clear recommendations that are easy to follow and can be utilized right and are not overly complicated or tough to use in some way.

Regards.

Collaboration is becoming more important over time. The body of scientific knowledge and technology is expanding so rapidly that it’s becoming more difficult for individual investigators to master the essential skills and knowledge necessary to produce currently relevant work.

Hi Doaa, 

Our lab regularly uses DAI when using the DSS model and published on this a few years ago. 

In it, we make reference to how we evaluate DAI that includes bleeding (In this case, bleeding: 0 (no blood), 1 (Hemoccult positive), 2 (Hemoccult positive and visual pellet bleeding), and 4 (gross bleeding)). 

Hope this helps!

-Janice 

Your question seems stil "open" ... but what is your question ?

Here attached you will find an article that seems to me to fit in with the "title" of your question.

Best regards

Robert

I share neither Anirban's nor Rangarajan's opinions ...

The C6 glioma model in rats is by far too immunogenic and the tumor take never reaches 100%. If you want an agressive model in rat, you can use the 9L gliosarcoma (see the attached article by Lefranc et al., Neurosurgery 2003). In syngeneic mice, you can use the G261 glioma model (see Vershuere et al., Int J Cancer 2015).

With respect to human gliomas, you must use those models that diffusely invade the brain parenchyma, which is never the case with the U87 model. The U87 model is excellent to study anti-angiogenic compounds (Lamour et al., Int J Cancer 2010) but it actually does not mimik what happens in clinics (see Camby et al., JNEN 2002).

The Hs683 oligodendroglioma and the U373 astroglioma models mimik relatively well what happens in clinic, both in terms of spreading in the brain and chemosensitivity (see Branle et al., Cancer 2002; Lefranc et al., Neurosurgery 2008; Mathieu et al., Neoplasia 2008).

Best regards

Robert 

Thanks alot for these information

Thanks, so I really have to use a Software.

This is difficult in clinical practise

I have been a neuropathologist for over 30 years and I specialize in brain tumor diagnosis, and I have never heard this term either.  I think there is some sort of miscommunication, and as suggested, it can best be cleared up by the person who made the diagnosis.   We would all like follow-up when you get it, I think.

As a malignant neoplasm, if possible, ETV would be a good solution. Revising the shunt ia always an option, but CSF dissemination and meningeal gliomatose have to be rulled out.

Thank you all for your answers!

Anyway, any more details or informations will be always welcome!!

Thank you

I have worked extensively with the Yoneda et al. (2001) line from UT San Antonio which we have validated in vivo. Contact info: Dr. Toshiyuki Yoneda, The Division of Endocrinology and Metabolism, Department of Medicine, University of Texas Health Science Center at San Antonio, Mailing Code: 7877, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, USA

Please find enclosed an article? However, this is an opinion, not guidelines.

@Francisco sanchez-bayo: I am glad for the link you provided and also for your interest to help me. Although I am more interested discussion at ResearchGate, but may try to contact Dr Junko Kimura-Kiroda, as well. However, I am still in contact with some professors in my country and waiting their response. Widespread collaboration in science has been made very easy through social media. I also hope different views, suggestions and corrections/remarks/.comments here.

If you're asking about diagnostic markers then the only one for brain tumours is the absence of INI1 on IHC, which gives the diagnosis of ATRT.

There are also obviously combinations of different IHC stains and pathology which are used for brain tumour diagnosis and grading but there is some grey areas here. INI1 is the only one that is "bulletproof".

PRMT5 has been studied in its role in tumor growth promotion; related to its suppressive effect on transcription of tumor suppressor genes, Rb family, ST7 and nonmetastasing nm23 protein arginine . The overexpression in brain tumor might be accompanied by reduced expression of the functional tumor suppressor proteins.

Nowadays all are concentrating on tumor is there any interesting problem related to brain image segmentation ,give me ideas in this regard please

We work on image processing, segmentation too. We can talk about it if you want. Do not hesitate to contact me!

Thank you Dr. Can I have your mail-id for further discussion?

Radiotherapy is also used for brain tumor. It is the use of high energy x-rays or gamma rays to kill cancer cell.

Hi Joachim

Thanks for comments. but i read CD 15 also the marker of cancer stem cells, but i found only few study...